Delhi HC Rejects Plea in Vimal Elaichi Surrogate Ad Row: Delhi High Court Bollywood Actors Notice Explained

NEW DELHI: The Delhi High Court has dismissed a petition filed by PB Agro LLP, the master licensee associated with Vimal Elaichi, challenging show-cause notices issued by Maharashtra’s Food and Drug Administration (FDA) to actors Shah Rukh Khan, Ajay Devgn and Tiger Shroff. The ruling adds a fresh legal development to the Vimal Elaichi Surrogate Ad Row, while the Delhi High Court Bollywood Actors Notice dispute continues to draw attention across Bollywood and the advertising industry.

What the Delhi High Court decided

Justice Swarana Kanta Sharma dismissed the petition on September 14, 2026, holding that the Delhi High Court was not the appropriate forum to examine the Maharashtra FDA action. The court relied on the doctrine of forum conveniens, under which a court may decline to hear a dispute when another jurisdiction is more appropriate and convenient. The Indian Express reported that the plea was rejected on territorial-jurisdiction grounds.

The ruling is important because it does not amount to a final finding that the three actors breached advertising law. The Vimal Elaichi Surrogate Ad Row therefore remains unresolved on its underlying merits.

Why Shah Rukh Khan, Ajay Devgn and Tiger Shroff received notices

The Maharashtra FDA issued show-cause notices to the three celebrities over advertisements for Vimal Elaichi. Regulators alleged that the campaigns could amount to surrogate promotion of Vimal pan masala.

PB Agro LLP argued that Vimal Elaichi is a cardamom product and maintained that its endorsement arrangements and advertising campaign comply with applicable law. The company approached the Delhi High Court seeking to challenge the regulatory action.

That distinction is central to the Vimal Elaichi Surrogate Ad Row: allegations by a regulator are not the same as a final finding of liability against the celebrities. The actors were recipients of the notices, rather than petitioners in the Delhi case.

What the Delhi High Court notice ruling means

The dismissal means the Delhi High Court Bollywood Actors Notice challenge has failed at the jurisdiction stage. The court did not decide whether the advertisements ultimately constitute unlawful surrogate advertising.

The Maharashtra proceedings can therefore continue, subject to further legal remedies and arguments available to the parties. The dispute raises a wider question about whether advertising for an apparently separate product can create an association with a regulated or restricted product.

For the three stars, the Delhi High Court Bollywood Actors Notice controversy places renewed attention on the regulatory responsibilities surrounding high-profile endorsement deals.

Why the case matters for Bollywood advertising

The Vimal Elaichi Surrogate Ad Row extends beyond the three celebrities involved. Shah Rukh Khan, Ajay Devgn and Tiger Shroff are among India’s most recognisable film stars, giving the regulatory dispute unusually broad visibility across the Bollywood section of The Reportiva.

The case also highlights the potential regulatory exposure attached to celebrity advertising when brands operate alongside products associated with tobacco or pan masala. For advertisers, agencies and celebrities, the dispute illustrates why the precise identity, presentation and marketing context of an endorsed product can become legally significant.

The Delhi High Court Bollywood Actors Notice issue is consequently likely to remain relevant even though the Delhi petition itself has been dismissed.

What happens next

The latest development is procedural rather than a final ruling on the advertising allegations. PB Agro LLP has not obtained relief from the Delhi High Court against the Maharashtra FDA action, leaving the underlying regulatory dispute open.

The Vimal Elaichi Surrogate Ad Row could now continue through proceedings in Maharashtra. Until a competent authority or court makes a substantive determination, claims that the advertisements definitively violated the law should remain described as allegations.

For Bollywood, the Delhi High Court Bollywood Actors Notice dispute is another reminder that celebrity endorsement contracts can trigger regulatory scrutiny far beyond a film star’s promotional role. The case could also become relevant to future debates over surrogate advertising and the limits of celebrity brand endorsements.